Skip to main content
 

Biosimilars Forum Statement on CMS Announcement Regarding Medicare Advantage

WASHINGTON, D.C., August 9, 2018 – The Biosimilars Forum is encouraged by the announcement from the Centers for Medicare and Medicaid Services (CMS) and their continued efforts to increase access to biosimilars and drive competition to improve affordability for patients. The Biosimilars Forum believes that patient choice is important and they should be provided with transparent information to make informed decisions about their care. Additionally, the Forum believes that physicians ability to prescribe clinically appropriate medications should not be compromised.

The Forum will continue to evaluate this proposal and looks forward to serving as a resource to the Administration to help shape the plan to increase competition, development, and access to biosimilars for Medicare patients.

About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org, @USbiosimilars, or Facebook/USBiosimilars to follow related conversations and join the dialogue.

Contact:
Anthony Hogrebe, Marathon Strategies
Anthony@marathonstrategies.com

Date

Thursday, August 9, 2018